Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coherus Oncology Inc (CHRS)

Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 288,479
  • Shares Outstanding, K 149,471
  • Annual Sales, $ 266,960 K
  • Annual Income, $ 28,510 K
  • EBIT $ -178 M
  • EBITDA $ -172 M
  • 60-Month Beta 1.05
  • Price/Sales 0.81
  • Price/Cash Flow 6.04
  • Price/Book 2.33

Options Overview Details

View History
  • Implied Volatility 213.48% (-49.43%)
  • Historical Volatility 98.49%
  • IV Percentile 55%
  • IV Rank 21.32%
  • IV High 670.52% on 11/17/25
  • IV Low 89.67% on 08/13/25
  • Expected Move (DTE 10) 0.5185 (26.87%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,664
  • Volume Avg (30-Day) 551
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 21,208
  • Open Int (30-Day) 23,321
  • Expected Range 1.4115 to 2.4485

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +243,758.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5700 +22.93%
on 03/03/26
2.2000 -12.27%
on 02/10/26
-0.1300 (-6.31%)
since 02/09/26
3-Month
1.2700 +51.97%
on 12/29/25
2.6158 -26.22%
on 01/27/26
+0.6400 (+49.61%)
since 12/09/25
52-Week
0.7100 +171.83%
on 06/23/25
2.6158 -26.22%
on 01/27/26
+0.8900 (+85.58%)
since 03/07/25

Most Recent Stories

More News
Coherus Oncology: Q4 Earnings Snapshot

Coherus Oncology: Q4 Earnings Snapshot

CHRS : 1.9300 (+6.04%)
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025...

CHRS : 1.9300 (+6.04%)
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market...

CHRS : 1.9300 (+6.04%)
Coherus Oncology to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations...

CHRS : 1.9300 (+6.04%)
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE)...

CHRS : 1.9300 (+6.04%)
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of...

CHRS : 1.9300 (+6.04%)
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common...

CHRS : 1.9300 (+6.04%)
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 1.0600 (unch)
IDYA : 35.08 (+5.69%)
ZLAB : 19.12 (-2.15%)
CHRS : 1.9300 (+6.04%)
HALO : 68.14 (+1.14%)
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference...

CHRS : 1.9300 (+6.04%)
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

-Coherus Oncology formally introduces non-proprietary name:  tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical...

CHRS : 1.9300 (+6.04%)

Business Summary

Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 2.1367
2nd Resistance Point 2.0433
1st Resistance Point 1.9867
Last Price 1.9300
1st Support Level 1.8367
2nd Support Level 1.7433
3rd Support Level 1.6867

See More

52-Week High 2.6158
Last Price 1.9300
Fibonacci 61.8% 1.8878
Fibonacci 50% 1.6629
Fibonacci 38.2% 1.4380
52-Week Low 0.7100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar